This content is machine translated SGLT2 inhibitor convinces Dapagliflozin may score well in nephro- and cardioprotection Patients with diabetic nephropathy can now be effectively treated with SGLT2 inhibitors. They are also said to have cardioprotective effects. Dapagliflozin is now the first and only antidiabetic agent approved…
View Post 7 min This content is machine translated Diabetes Management Nephro- and cardioprotection as an interdisciplinary challenge Early detection and treatment of renal dysfunction and cardiovascular risk factors in type 2 diabetes mellitus is essential. Experts see a need for action in this area, especially with regard…
View Post 3 min This content is machine translated Hyperkalemia How the Guideline Comes to the Bedside: Hyperkalemia Management Up to Date Patients with chronic heart or kidney failure often suffer from hyperkalemia. The use of RAAS inhibitors in particular may increase the risk of this life-threatening electrolyte disturbance. Therefore, therapy of…
View Post 3 min This content is machine translated Diabetic kidney disease Canagliflozin approved in fast track for diabetic nephropathy Kidney protection is extremely important for diabetes sufferers. Recently, canagliflozin became the first SGLT-2 inhibitor in Switzerland to receive a marketing authorization extension to reduce the risk of progression to…
View Post 3 min This content is machine translated Chronic renal failure Dapagliflozin meets primary endpoints ahead of schedule The Phase III DAPA-CKD study will be terminated earlier than planned due to proven efficacy in patients with chronic renal failure. Dapagliflozin is the first SGLT2 inhibitor to show meaningful…
View Post 6 min This content is machine translated Type 2 diabetes: SGED Recommendations 2020 Update Cardiovascular risk stratification and personalized therapy. When prescribing antidiabetic therapy, other criteria are relevant today in addition to blood glucose control. The cardiac benefit of SGLT2 inhibitors and GLP1 analogues has been incorporated into international guidelines…
View Post 11 min This content is machine translated Hypertension in practice High blood pressure – What the family doctor needs to know After a confirmed diagnosis of arterial hypertension, one should assess the severity, overall cardiovascular risk, and any organ damage present. First-line antihypertensives are RAAS blockers alone or combined with Ca…
View Post 7 min This content is machine translated Chronic renal failure Aspects of the treatment of metabolic acidosis Chronic metabolic acidosis is a common complication in renal failure patients. The disease is associated with accelerated progression of chronic kidney disease and increased all-cause mortality. Acidosis correction via diet,…
View Post 2 min This content is machine translated Renal cell carcinoma Therapy with mind and system Renal cell carcinoma is one of the common malignant tumors in adults. In terms of drug treatment options, this tumor entity has undergone more rapid change in recent years than…
View Post 3 min This content is machine translated Diabetic nephropathy Inhibition of sodium-glucose transporter type 2 has a renoprotective effect Diabetic nephropathy is the most common cause of chronic kidney failure – and one of the most common consequences of diabetes mellitus. The introduction of sodium-glucose transporter type 2 (SGLT2)…
View Post 4 min This content is machine translated Renal failure SGLT-2 inhibitors: a breakthrough in nephroprotection? Research into treatments for chronic kidney disease has stagnated for a long time. Now there is good news. SGLT2 inhibitors and GLP-1 are promising hopefuls, as recent findings show.
